NAD+

NAD⁺, or nicotinamide adenine dinucleotide, emerged from early twentieth-century research into the chemical reactions that allow cells to extract energy from nutrients. It was first recognized as a heat-stable factor required for fermentation and was later identified as a nucleotide coenzyme involved in oxidation–reduction reactions. For much of the twentieth century, NAD⁺ was studied primarily as an electron carrier. In its oxidized form, NAD⁺ accepts electrons to become NADH; NADH can then transfer those electrons through metabolic pathways that support ATP production. The research field broadened when scientists found that NAD⁺ is also consumed by enzymes involved in cellular regulation. PARP enzymes use it during responses to DNA damage, while sirtuins use it in deacylation reactions connected to metabolism and stress signaling.¹ ² These discoveries reframed NAD⁺ as both a metabolic cofactor and a signaling substrate. More recent research has examined how NAD⁺ availability changes with age and metabolic stress, along with whether precursors such as NR and NMN can alter cellular NAD⁺ pools.³ Most outcome-focused longevity claims remain investigational.

NAD⁺ connects energy metabolism with several enzyme-driven maintenance and signaling systems. In redox reactions, NAD⁺ accepts electrons during glycolysis, the citric-acid cycle and related pathways, forming NADH. NADH then supplies electrons to the mitochondrial electron-transport chain, helping create the proton gradient used for ATP synthesis.⁴ ⁵ NAD⁺ also functions as a consumed substrate rather than only as a recyclable electron carrier. Sirtuins use NAD⁺ during deacylation reactions that influence gene regulation, metabolism and cellular stress responses. PARP enzymes consume NAD⁺ to build ADP-ribose chains during DNA-damage signaling and repair.⁴ ⁶ CD38 and related enzymes cleave NAD⁺ to generate signaling molecules involved in calcium mobilization. Because sirtuins, PARPs and CD38 all draw from NAD⁺ pools, cellular availability reflects a balance among biosynthesis, salvage, redox cycling and enzymatic consumption. NAD⁺ therefore does not act through one receptor. It functions as a biochemical cofactor and substrate whose effects depend on cell type, compartment and metabolic state.

NAD⁺, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) occupy different positions in NAD⁺ metabolism. NAD⁺ is the coenzyme used in redox and enzyme-driven reactions, while NMN and NR are precursor molecules that cells can use to replenish NAD⁺ pools.⁶ NR is phosphorylated to form NMN, which is then converted into NAD⁺. NMN enters one step later in this pathway, although its absorption is more complex than that sequence alone suggests: depending on tissue and route, extracellular NMN may be transported directly or converted to NR before cellular uptake.⁶ Both precursors have increased NAD⁺ or related metabolites in human studies, but their clinical outcome evidence remains limited. NR has a longer human research record, while NMN has been examined in a growing number of early trials. Animal findings—including long-term NMN studies—should not be assumed to predict human outcomes.⁷ Direct NAD⁺ administration supplies the final molecule extracellularly, but it does not necessarily guarantee intact entry into every cell; metabolism and transport remain important variables. Current evidence does not establish one approach as consistently superior, and direct head-to-head studies are limited.